Abstract:Pamiparib, an investigational, selective inhibitor of PARP1/2, has PARP-DNA complex trapping capabilities. The first-in-human study (NCT02361723) established the pamiparib phase II dose as 60 mg po BID. Responses were reported in BRCA mutated or wild-type and platinum-sensitive/resistant aOC. Here we present phase II results from an ongoing phase I/II study in Chinese pts with advanced solid tumors (NCT03333915). Patients with platinum-sensitive (cohort 1) and platinum-resistant (cohort 2) aOC were enrolled. Patients with known/suspected deleterious germline BRCA1/2 mutation and ≥2 prior lines of chemotherapy were eligible. The primary endpoint was objective response rate (ORR) assessed by an independent review committee (ORRIRC) per RECIST v1.1. As of 2 Feb 2020, 113 pts (cohort 1, n=90; cohort 2, n=23) were enrolled. Median age was 54 yr (range: 34-79), 25.6% (n=29) of pts had received ≥4 prior systemic chemotherapy lines, and 54.0% (n=61) of pts had an ECOG score of 1 at study entry. At data cutoff, median follow-up was 12.2 mo (range: 0.2-21.5). Across both cohorts, pamiparib showed preliminary antitumor activity (Table). In cohort 1, confirmed ORRIRC was 64.6%, median DoR was 14.5 mo (95% CI, 11.1-NE), progression-free survival (PFS) was 15.2 mo (95% CI, 10.35-NE), and median overall survival (OS) was not yet mature. In cohort 2, confirmed ORRIRC was 31.6%, median DoR was 11.1 mo (95% CI, 4.21-NE), median PFS was 6.2 mo (95% CI, 4.11-NE), and median OS was 13.6 mo (95% CI, 7.13-NE). Overall, the most common treatment-related AE was anemia (any grade, 89%; grade ≥3, 42%); following a per-protocol proposed dose modification algorithm, the incidence of grade ≥3 anemia was reduced to 25.6%.Table:Efficacy-evaluable populationCohort 1 (n=82)Cohort 2 (n=19)Best overall response, n (%)Complete response8 (9.8)0 (0)Partial response45 (54.9)6 (31.6)Stable disease25 (30.5)12 (63.2)Progressive disease4 (4.9)1 (5.3)Objective response rate, % (95% CI)Confirmed64.6 (53.3-74.9)31.6 (12.6-56.6)Disease control rate, % (95% CI)95.1 (88.0-98.7)94.7 (74.0-99.9)Clinical benefit rate, % (95% CI)74.4 (63.6-83.4)52.6 (28.9-75.6)Time to response, median mo (range)1.68 (1.3-6.3)1.38 (1.2-1.4)Duration of response, median mo (95% CI)14.5 (11.1-NE)11.1 (4.21-NE)PFS, median mo (95% CI)15.2 (10.35-NE)6.2 (4.11-NE)Abbreviations: NE, not estimable; PFS, progression-free survival. Open table in a new tab Abbreviations: NE, not estimable; PFS, progression-free survival. Promising antitumor activity was observed in pts with platinum-sensitive/resistant aOC. Pamiparib was generally tolerated, with no new safety signals. Pamiparib is being evaluated as monotherapy and combination therapy for other solid tumors.

Supplementary Figure from Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study

Pamiparib in Patients with Locally Advanced or Metastatic HER2-negative Breast Cancer with Germline BRCA Mutations: a Phase II Study

A Phase II Trial of Cytoreductive Surgery Combined with Niraparib Maintenance in Platinum-Sensitive, Secondary Recurrent Ovarian Cancer: SGOG SOC-3 Study

Pamiparib Monotherapy for Patients with Germline BRCA1/2 -Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

998TiPPamiparib, a novel PARP 1/2 inhibitor, monotherapy for gBRCAm patients with recurrent ovarian, fallopian, and primary peritoneal cancer: An open-label, multicenter, phase II trial in China

Supplementary Figure S7 from Germline Mutations of Holliday Junction Resolvase Genes in Multiple Primary Malignancies Involving Lung Cancer Lead to PARP Inhibitor Sensitization

A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutation.

Supplementary Figure S1 from Germline Mutations of Holliday Junction Resolvase Genes in Multiple Primary Malignancies Involving Lung Cancer Lead to PARP Inhibitor Sensitization

Olaparib Maintenance Therapy in Patients (pts) with a BRCA1 And/or BRCA2 Mutation (brcam) and Newly Diagnosed Advanced Ovarian Cancer (OC): SOLO1 China Cohort

Olaparib Maintenance Monotherapy in Chinese Patients with Platinum‐sensitive Relapsed Ovarian Cancer: China Cohort from the Phase III SOLO2 Trial

An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline BRCA1/2 Mutation and Platinum-sensitive Recurrent Ovarian Cancer

PR072/#1519 Effort: Clinical and Molecular Features Associated with Clinical Benefit from Adavosertib with or Without Olaparib in Recurrent Ovarian Cancer Following Progression on PARP Inhibition (NCT03579316)

Supplementary Figure 1 from Pyrotinib Treatment in Patients with HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data

Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti–PD‐L1, for BRCA wild‐type, platinum‐sensitive, recurrent ovarian cancer

820P Phase II Study of Pamiparib in Chinese Patients (pts) with Advanced Ovarian Cancer (Aoc)

Supplementary Tables S1-S4 from the BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin

Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer

Supplementary Figure from Phase II Study of TQB2450, a Novel PD-L1 Antibody, in Combination with Anlotinib in Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma

Pamiparib dose escalation in Chinese patients with non‐mucinous high‐grade ovarian cancer or advanced triple‐negative breast cancer

Supplemental Figure 1 from Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03